Special Issue "Multi-Targeted Natural Products as Therapeutics"
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".
Deadline for manuscript submissions: 22 January 2024 | Viewed by 14365
Special Issue Editors
Interests: effectiveness and safety of natural products; herbal-drug interactions; pediatric clinical pharmacology
Interests: effectiveness and safety of natural products; herbal-drug interactions; pediatric clinical pharmacology
Interests: effectiveness and safety of natural products; herbal-drug interactions; pediatric clinical pharmacology
Special Issue Information
Dear Colleagues,
For centuries, humans have used medicinal herbs and other natural products to treat and prevent various diseases. In the 20th century, many new drugs approved by regulatory agencies worldwide were isolated from natural products. Consequently, medicinal herbs and other natural products represent a valuable resource and source for drug development.
Nowadays, we realize that the pathogenesis of many diseases is multifactorial. Therefore, successful treatment of these diseases should target several pathways for successful disease treatment. Conventional drugs, which are single-molecule medicines, usually target a single pathway or specific body function. Unlike conventional drugs, folk medicine traditionally uses one or more natural products to prepare extracts, infusions, and decoctions. A preparation from even one medicinal herb may contain hundreds, if not thousands, of bioactive molecules. These molecules target functions of different organs and systems and potentiate or antagonize the functions of the preparation's other bioactive molecules. For example, many, if not all, antibacterial and antiviral drugs also possess immunomodulatory properties. Another example is that anti-cancer remedies may activate or suppress various pathways involved in cancer development and progression.
In this Special Issue, we aim to summarize and examine the latest research findings, identifying natural products targeting multiple pathways and body functions that can lead to the successful treatment of multifactorial diseases.
On 28 September 2023, we chaired a webinar with the theme "Can phytomedicine target organ and system functions via multiple pathways?" (https://pharmaceuticals-2.sciforum.net/). Click the link to find the recordings of this webinar to watch, re-watch, and share with your colleagues!
Dr. Elena Y. Enioutina
Dr. Kathleen M. Job
Prof. Dr. Catherine Sherwin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- natural products
- medicinal herbs
- marine products
- animal products
- bioactive compounds
- multifactorial diseases
- multi-targeting phytochemicals
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Tentative Abstract:
The metabolic rewiring is considered now as one of the “Hallmarks of cancer” and opens a window for therapeutic intervention. However, metabolic reprogramming is a complex process full of various complementary and substitute pathways. It provides malignant cells with adaptational plasticity, energy and “building blocks” for biosynthetic requirements, proliferation and invasion, antioxidant defense, resistance to anticancer immunity and therapeutics, etc. Today, it is well known that highly selective inhibition of only one of the processes in a tumor cell often leads to a limited response, and subsequently to the emergence of resistance. Therefore, to increase the overall effectiveness of antitumor drugs, it is advisable to use multitarget agents that can simultaneously suppress several key processes in the tumor cell. This review is focused on a group of plant-derived natural compounds which simultaneously target different pathways of cancer-associated metabolism including aerobic glycolysis, respiration, glutaminolysis, one-carbon metabolism, de novo lipogenesis and beta-oxidation of fatty acids. We have reviewed only those compounds which have inhibitory activity on several metabolic pathways as well as a number of key signaling pathways in cancer. The information about their pharmacokinetics in animals and human is also presented. Taken together, a number of known plant-derived compounds may target multiple metabolic and signaling pathways in various malognancies and bear a powerful potential for the further improvement of antineoplastic therapy.